Skip to main content

news

Freshfields Bruckhaus Deringer, Gibson, Dunn & Crutcher, King & Wood Mallesons and DLA Piper have advised Chinese biopharma company Hutchmed on its HK$4.17 billion ($537 million) secondary listing in Hong Kong.

Linklaters, Davis Polk & Wardwell and JunHe are counselling the joint sponsors and underwriters, namely Morgan Stanley Asia, Jefferies Hong Kong and China International Capital Corporation.

Listed on the AIM market of the London Stock Exchange since 2006, Hutchmed also has American Depositary Shares (ADSs) listed on the Nasdaq Global Select Market. It is a biopharmaceutical company focused on the discovery, development and commercialisation of targeted therapies and immunotherapies for the treatment of patients with cancer and immunological diseases.

Partners Kevin Cheung and Christopher Yip led the Linklaters team. Conyers is providing offshore legal advice to the issuer.

 

To contact the editorial team, please email ALBEditor@thomsonreuters.com.

Related Articles

Deals

Khaitan, JSA, Hogan Lovells guide $515 mln Waaree IPO

by Nimitt Dixit |

Khaitan & Co has advised Waaree Energies, India's largest manufacturer and exporter of solar modules, on its $515 million initial public offering, with JSA Advocates & Solicitors and Hogan Lovells guiding the bookrunning lead managers.

Deals

CAM, Khaitan guide Adani-backed Renew Exim’s $380 mln ITD acquisition

by Nimitt Dixit |

Cyril Amarchand Mangaldas has advised Adani Group's Dubai-based firm Renew Exim DMCC on its acquisition of a 46.64 percent stake in ITD Cementation India for around $380 million from Italian-Thai Development Public Company, who was represented by Khaitan & Co.

Deals

CAM, AZB, SAM, Latham advise on landmark $1.3 bln Swiggy IPO

by Nimitt Dixit |

Cyril Amarchand Mangaldas is advising SoftBank-backed Indian food and grocery delivery giant Swiggy on its much-anticipated initial public offering worth $1.3 billion, with AZB & Partners and Latham & Watkins advising the bookrunning lead managers.